MeiraGTx Holdings plc (MGTX)
MGTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$9.94
-4.24% on the day
Market cap
$954.7M
Small cap
Revenue · 2025
$81.4M
+144.6% on 2024
Net income · 2025
Net income not in SEC XBRL data
0.0% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | MGTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001735438 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $81.4M |
| Net income | Not in SEC XBRL data |
| Operating income | -$106.0M |
| Net margin | 0.0% |
| Operating margin | -130.2% |
| Revenue growth | +144.6% |
| Cash | $65.9M |
| Total assets | $244.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 11.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-16 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-09-23 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 507 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.7% |
| 1 month | -25.9% |
| 3 months | -23.4% |
| Year to date | +18.9% |
| 1 year | +20.7% |
| From 52-week high | -36.9% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CGEM | Cullinan Therapeutics Inc. | $14.10 | -5.69% | $907.4M |
| IMTX | Immatics N.V. | $6.83 | -5.27% | $1.0B |
| SLBT | SL Science Holding Limited | $1.53 | +1.32% | $858.0M |
| GLUE | Monte Rosa Therapeutics Inc. | $9.89 | -5.99% | $843.7M |
| ODTX | Odyssey Therapeutics Inc. | $17.24 | -5.59% | $828.5M |
| VOR | Vor Biopharma Inc. | $19.06 | -3.74% | $1.1B |
| REPL | Replimune Group Inc. | $12.11 | -7.34% | $1.1B |
| TSHA | Taysha Gene Therapies Inc. | $3.58 | -13.53% | $1.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier